Journal of the Bahrain Medical Society

Year 2022, Volume 34, Issue 3, Pages 52-56

http://doi.org/10.26715/jbms.34_3_9

Case Report

Pyridoxamine 5’-Phosphate Oxidase Deficiency: A Potentially Treatable Epileptic Encephalopathy

Lateefa Almutawea1*, Ayman Khalil2

Author Affiliation

1Pediatric Resident, Pediatrics and Neonatology Department, King Hamad University Hospital, Bahrain; Tel.: (+973) 36306290; Email: latifa.almutawea@gmail.com

2Consultant, Pediatric Neurology, Department of Clinical Neurosciences, Salmaniya Medical Complex, Bahrain; Tel.: (+973) 39900075; Email: aymanali131@gmail.com

*Corresponding author: Dr. Lateefa Almutawea, Pediatric Resident, Pediatrics and Neonatology Department, King Hamad University Hospital, Bahrain; Tel.: (+973) 36306290; Email: latifa.almutawea@gmail.com

Received date: January 01, 2022; Accepted date: March 01, 2022; Published date: September 30, 2022

For tables and figures, refer to PDF.


Abstract

Pyridoxal phosphate-responsive neonatal epileptic encephalopathy due to pyridoxamine-5-primephosphate oxidase deficiency is a rare cause of epileptic encephalopathy. A neonate with this condition presents early in life with refractory seizures which does not respond to conventional anti-epileptic medications, depressed level of consciousness, and severe psychomotor retardation if left untreated. Early initiation of active cofactor pyridoxal-5’-phophate can be curative. We are describing a rare neurometabolic condition; the first case in the Kingdom of Bahrain to the best of our knowledge.

Keywords: Pyridoxal-5’-phosphate, pyridoxamine 5’-phosphate oxidase, pyridoxine dependent epilepsy, epileptic encephalopathy, neonatal seizure